Business Standard

Morepen Laboratories surges 14% on USFDA approval for Baddi facility

The stock surged 14% to Rs 36.20 on the NSE after the company received USFDA approval for both its bulk drugs manufacturing facilities situated in Himachal Pradesh.

Morepen to go big on therapies for preventive cardiology & diabetology
Premium

SI Reporter Mumbai
Shares of Morepen Laboratories have surged 14% to Rs 36.20 per share on the National Stock Exchange (NSE) in intra-day trade on back of heavy volumes after the company announced that it has received United States Food and Drug Administration (USFDA) approval for both its bulk drugs manufacturing facilities situated in Himachal Pradesh.

“While the Baddi facility has got US FDA approval for the manufacture of bulk drug "Atorvastatin Calcium", a Cholesterol reducing drug, the Masulkhana facility has recently got the nod for manufacturing an anti-asthma bulk drug "Montelukast Sodium" for export to the US market,” Morepen Laboratories said

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jul 30 2018 | 1:46 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com